Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals
PLOS One · 25.06.2025 · 20 (6) · e0324807
DOI: 10.1371/journal.pone.0324807 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 25.06.2025. Verfasst von Kathy Sliwinski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Services and Outcomes Research, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America. Hauptthemen laut MEDLINE: Drug Approval, Clinical Trials as Topic, Patient Selection, Eligibility Determination. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AHRQ HHS, NINR NIH HHS, National Institute of Health Advanced Training in Nursing Outcomes Research.
Abstract (Originalsprache)
There has been substantial recent attention to the importance of diversity in clinical trials supporting US Food and Drug Administration (FDA) drug approvals, including both Congressional action and FDA guidance. One factor that can contribute to a lack of diverse enrollment is overly strict eligibility criteria not supported by scientific or safety considerations. The aim of this study was to examine equity-related eligibility criteria in pivotal trials supporting all new molecular entities and therapeutic biologics approved by FDA’s Center for Drug Evaluation and Research in 2022. We qualitatively coded these criteria, using a codebook developed through inductive and deductive methods. The codebook consisted of categories relevant to equitable inclusion across race, ethnicity, socioeconomic status, pregnancy, disability, and age; explanations of the potential relevance to equity, as well as potential scientific and regulatory justifications. We found that adolescents, pregnant/lactating individuals, and individuals with limited literacy were most commonly excluded and that about 1 trial in 5 excluded individuals based on weight/obesity, had general exclusions for hepatitis, or excluded adults aged 80 and up. Ultimately, our results indicate that several common eligibility criteria are likely to negatively influence equitable inclusion, especially based on age, pregnancy/lactation, and characteristics associated with race, ethnicity, and socioeconomic status. To minimize unnecessary equity-related exclusions, eligibility should focus on specific issues expected to influence safety or efficacy (e.g., liver function, drug interaction, uncontrolled comorbid disease), rather than blanket exclusion based on broad diagnoses or characteristics. Investigators, sponsors, institutional review boards, and regulators should scrutinize eligibility criteria with equity in mind.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Health Services and Outcomes Research, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
- Center for Health Outcomes and Policy Research, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania, United States of America.
- Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
- Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, Connecticut, United States of America.
- Program for Biomedical Ethics, Yale School of Medicine, New Haven, Connecticut, United States of America.
- Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
ORCID-Profile: Kathy Sliwinski
Förderung
- AHRQ HHS
- NINR NIH HHS
- National Institute of Health Advanced Training in Nursing Outcomes Research
- Agency for Healthcare Research and Quality Health Services Research Training program
- Arnold Ventures
- Greenwall Foundation
- NIH
- Food and Drug Administration
Zitieren
APA
Sliwinski, K., Miller, J. E., & Lynch, H. F. (2025). Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals. PLOS One, 20(6), e0324807. https://doi.org/10.1371/journal.pone.0324807
Vancouver
Sliwinski K, Miller JE, Lynch HF. Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals. PLOS One. 2025;20(6):e0324807. doi:10.1371/journal.pone.0324807
BibTeX
@article{Sliwinski2025,
author = {Sliwinski, Kathy and Miller, Jennifer E and Lynch, Holly Fernandez},
title = {Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {6},
pages = {e0324807},
doi = {10.1371/journal.pone.0324807}
}
EUVIMED